Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Diffuse midline glioma (DIPG)
H3 K27-altered tumours of the brainstem and midline, with no curative treatment: ONC201 and cell therapy trials.
Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
73
Phase 1 to 3, interventional
For relapsed or refractory disease
30%
22 trial titles name relapsed, refractory or recurrent disease
Led by industry
23%
17 trials with a company as lead sponsor
3 of the 73 diffuse midline glioma (dipg) trials are Phase 3; 8 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of diffuse midline glioma (dipg) (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 34 of 73 trials name no segment and are listed as Untagged.
Segment:All1L1L · Relapsed or refractoryAdjuvantAdvanced or metastaticH3 K27H3 K27 · Relapsed or refractoryRelapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Temozolomide Theodore S. Johnson | 1L · Relapsed or refractory | Small molecule | Ph2 | NCT04049669, NCT06639607, NCT05096481 |
| Temozolomide Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT04238819, NCT04239092 |
| Cyclophosphamide Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680, NCT04239092 |
| Temozolomide National Cancer Institute (NCI) | Untagged | Small molecule | Ph1/Ph2 | NCT05413304, NCT01837862 |
| Temozolomide Memorial Sloan Kettering Cancer Center | H3 K27 | Small molecule | Ph1/Ph2 | NCT07223034, NCT07562971 |
| Abemaciclib Eli Lilly and Company | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT04238819 |
| Cyclophosphamide Theodore S. Johnson | 1L · Relapsed or refractory | Small molecule | Ph2 | NCT04049669 |
| Olutasidenib + TMZ Rigel Pharmaceuticals | Advanced or metastatic | Small molecule | Ph2 | NCT06161974 |
| Palbociclib Pfizer | Relapsed or refractory | Small molecule | Ph2 | NCT03709680 |
| Paxalisib University of California, San Francisco | Relapsed or refractory | Small molecule | Ph2 | NCT05009992 |
| Ribociclib Nationwide Children's Hospital | Advanced or metastatic | Small molecule | Ph2 | NCT05843253 |
| Rucaparib Incyte Corporation | Advanced or metastatic | Small molecule | Ph1/Ph2 | NCT02711137 |
| Ruxolitinib Incyte Corporation | Advanced or metastatic | Small molecule | Ph1/Ph2 | NCT02711137 |
| Temozolomide Sabine Mueller, MD, PhD | 1L | Small molecule | Ph1/Ph2 | NCT07389278 |
| Temozolomide Nationwide Children's Hospital | Advanced or metastatic | Small molecule | Ph2 | NCT05843253 |
| Tovorafenib Nationwide Children's Hospital | Advanced or metastatic | Small molecule | Ph2 | NCT07206849 |
| Cyclophosphamide University of California, San Francisco | Untagged | Small molecule | Ph1 | NCT05478837, NCT04196413 |
| abemaciclib + temozolomide National Cancer Institute (NCI) | Untagged | Small molecule | Ph1 | NCT05413304 |
| Cilengitide Centre Oscar Lambret | Untagged | Small molecule | Ph1 | NCT01165333 |
| Cilengitide dose escalation Centre Oscar Lambret | Untagged | Small molecule | Ph1 | NCT01165333 |
| Cyclophosphamide + Fludarabine Lymphodepletive Conditioning University of Florida | Untagged | Small molecule | Ph1 | NCT03396575 |
| Pre-operative abemaciclib National Cancer Institute (NCI) | Untagged | Small molecule | Ph1 | NCT05413304 |
| Savolitinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph1 | NCT03598244 |
Assets over time
73 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Everolimus | Gustave Roussy, Cancer Campus, Grand Paris | |
| Dordaviprone | Jazz Pharmaceuticals | |
| Temozolomide | Memorial Sloan Kettering Cancer Center | |
| Doxorubicin | InSightec | |
| ADI-PEG 20 | Sabine Mueller, MD, PhD | |
| Selinexor | National Cancer Institute (NCI) | |
| Indoximod | Theodore S. Johnson | |
| PEP-CMV vaccine | Washington University School of Medicine | |
| H3K27M-EIEs | Shenzhen Geno-Immune Medical Institute | |
| VRT106 for injection | Guangzhou Virotech Pharmaceutical Co., Ltd. | |
| BCB-276 | BrainChild Bio, Inc | |
| ACT001 | Nationwide Children's Hospital | |
| Tovorafenib | Nationwide Children's Hospital | |
| Palbociclib | Pfizer | |
| FACT Complex-targeting Curaxin CBL0137 | Children's Oncology Group | |
| Opdualag | Nationwide Children's Hospital | |
| Eflornithine | Milton S. Hershey Medical Center | |
| Olutasidenib + TMZ | Rigel Pharmaceuticals | |
| PEP-CMV | Nationwide Children's Hospital | |
| LSAM-Cisplatin | NanOlogy, LLC | |
| Mebendazole | Julie Krystal | |
| LUTATHERA® | Nationwide Children's Hospital | |
| ONC201 | University of California, San Francisco | |
| Dendritic cell vaccination +- conventional next-line treatment | University Hospital, Antwerp | |
| Ribociclib | Nationwide Children's Hospital | |
| Abemaciclib | Eli Lilly and Company | |
| SIACI of cetuximab and bevacizumab | University of Miami | |
| Cobolimab | GlaxoSmithKline | |
| INCB057643 | Incyte Corporation | |
| Antineoplaston therapy | Burzynski Research Institute |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07869524 IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma Single-country: China (1 site) Decision brief → | Ph3 | Shandong Cancer Hospital and Institute | not yet recruiting | 2026-10-09 | 2030-12-31 |
| ACTION · NCT05580562 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) 18 countries, 41% of sites in the US Decision brief → | Ph3 | Jazz Pharmaceuticals | recruiting | 2022-10-14 | 2028-06 |
| BIOMEDE 2 · NCT05476939 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 8 countries, 0% of sites in the US Decision brief → | Ph3 | Gustave Roussy, Cancer Campus, Grand Paris | recruiting | 2022-07-27 | 2028-09 |
| TIGER-1 · NCT07767110 Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response No sites listed Decision brief → | Ph1/Ph2 | NanOlogy, LLC | not yet recruiting | 2026-08-17 | 2029-12 |
| NCT07680439 Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). Single-country: United States (6 sites) Decision brief → | Ph2 | BrainChild Bio, Inc | recruiting | 2026-07-02 | 2028-10 |
| NCT07644312 Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG No sites listed Decision brief → | Ph2 | Nationwide Children's Hospital | not yet recruiting | 2026-06-12 | 2033-03-01 |
| NCT07589257 A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma Single-country: China (1 site) Decision brief → | Ph2 | Guangzhou Virotech Pharmaceutical Co., Ltd. | recruiting | 2026-05-15 | 2028-06-30 |
| FIDES · NCT07562971 Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES) Single-country: Netherlands (2 sites) Decision brief → | Ph1/Ph2 | UMC Utrecht | not yet recruiting | 2026-05-01 | 2030-11 |
| NCT07501156 H3K27M-specific Immune Effector Cells Targeting DMG/DIPG Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2026-03-30 | 2029-12-31 |
| NCT07389278 Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Sabine Mueller, MD, PhD | not yet recruiting | 2026-02-05 | 2032-06-30 |
| NCT07206849 Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) No sites listed Decision brief → | Ph2 | Nationwide Children's Hospital | not yet recruiting | 2025-10-03 | 2030-02 |
| NCT06838676 ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas 5 countries, 60% of sites in the US Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2025-02-21 | 2028-07 |
| PRiME II · NCT06639607 PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Washington University School of Medicine | suspended | 2024-10-15 | 2031-08-31 |
| NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer 6 countries, 30% of sites in the US Decision brief → | Ph1/Ph2 | GlaxoSmithKline | active not recruiting | 2024-07-26 | 2026-10-13 |
| NCT06465199 Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Single-country: United States (14 sites) Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-06-18 | 2033-05 |
| NCT06161974 Study of Olutasidenib and Temozolomide in HGG 7 countries, 55% of sites in the US Decision brief → | Ph2 | Rigel Pharmaceuticals | recruiting | 2023-12-08 | 2029-06 |
| NCT05956821 Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Miami | recruiting | 2023-07-21 | 2029-10-01 |
| NCT05843253 Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant 6 countries, 55% of sites in the US Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2023-05-06 | 2029-08-31 |
| NCT05630209 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | InSightec | active not recruiting | 2022-11-29 | 2026-06 |
| NCT05615623 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG Single-country: Canada (1 site) Decision brief → | Ph1/Ph2 | InSightec | active not recruiting | 2022-11-14 | 2026-06 |
| NCT05278208 Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Single-country: United States (4 sites) Decision brief → | Ph1/Ph2 | Nationwide Children's Hospital | recruiting | 2022-03-14 | 2028-11 |
| NCT05099003 A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) 4 countries, 86% of sites in the US Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | active not recruiting | 2021-10-29 | 2027-09-30 |
| NCT05096481 PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Single-country: United States (13 sites) Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2021-10-27 | 2028-06-15 |
| NCT05077735 Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial Single-country: United States (2 sites) Decision brief → | Ph2 | Mayo Clinic | active not recruiting | 2021-10-14 | 2026-08-26 |
| PNOC022 · NCT05009992 Combination Therapy for the Treatment of Diffuse Midline Gliomas 6 countries, 59% of sites in the US Decision brief → | Ph2 | University of California, San Francisco | recruiting | 2021-08-18 | 2027-12-31 |
| ADDICT-pedGLIO · NCT04911621 Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma Single-country: Belgium (1 site) Decision brief → | Ph1/Ph2 | University Hospital, Antwerp | completed | 2021-06-03 | 2025-08-31 |
| NCT04870944 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma 2 countries, 97% of sites in the US Decision brief → | Ph1/Ph2 | Children's Oncology Group | recruiting | 2021-05-04 | 2026-12-31 |
| NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma 8 countries, 48% of sites in the US Decision brief → | Ph1/Ph2 | Eli Lilly and Company | completed | 2020-01-23 | 2024-03-15 |
| NCT04049669 Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Single-country: United States (5 sites) Decision brief → | Ph2 | Theodore S. Johnson | active not recruiting | 2019-08-08 | 2026-09-21 |
| NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors 13 countries, 67% of sites in the US Decision brief → | Ph2 | Pfizer | completed | 2018-10-17 | 2024-08-26 |
| NCT03330197 A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Alaunos Therapeutics | terminated | 2017-11-06 | 2021-09-10 |
| NCT02742883 A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) Single-country: United States (1 site) Decision brief → | Ph2 | Burzynski Research Institute | suspended | 2016-04-19 | 2028-03 |
| NCT02711137 Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies 3 countries, 89% of sites in the US Decision brief → | Ph1/Ph2 | Incyte Corporation | terminated | 2016-03-17 | 2019-02-13 |
| NCT01837862 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Julie Krystal | active not recruiting | 2013-04-23 | 2027-03 |
| LIFT · NCT07796061 Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT) Single-country: United States (1 site) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2026-08-31 | 2031-12 |
| NCT07664176 NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2026-06-24 | 2030-12 |
| MRG003 · NCT07584499 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Single-country: China (1 site) Decision brief → | Ph1 | Sun Yat-sen University | recruiting | 2026-05-13 | 2027-05-30 |
| NCT07455045 A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) Single-country: China (1 site) Decision brief → | Ph1 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | not yet recruiting | 2026-03-06 | 2027-12-01 |
| GABRIEL · NCT07331064 Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor No sites listed Decision brief → | Ph1 | Sarah Rumler | not yet recruiting | 2026-01-09 | 2030-11-15 |
| NCT07223034 A Study of 177Lu-PSMA-617 in People With Gliomas Single-country: United States (7 sites) Decision brief → | Ph1 | Memorial Sloan Kettering Cancer Center | recruiting | 2025-10-31 | 2027-10 |
| NCT07076498 Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation Single-country: United States (1 site) Decision brief → | Ph1 | M.D. Anderson Cancer Center | recruiting | 2025-07-22 | 2029-12-31 |
| Peds IMPACT · NCT06946680 IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) Single-country: United States (1 site) Decision brief → | Ph1 | University of Florida | not yet recruiting | 2025-04-27 | 2030-12 |
| NCT06896110 Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma Single-country: United States (1 site) Decision brief → | Ph1 | Andrew P. Groves | enrolling by invitation | 2025-03-26 | 2028-03 |
| NCT06894979 Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma Single-country: United States (22 sites) Decision brief → | Ph1 | Children's Oncology Group | active not recruiting | 2025-03-26 | 2028-03-31 |
| NCT06860594 Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma Single-country: United States (43 sites) Decision brief → | Ph1 | National Cancer Institute (NCI) | recruiting | 2025-03-06 | 2027-06-30 |
| NCT06806228 Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) 3 countries, 0% of sites in the US Decision brief → | Ph1 | Petrov, Andrey | suspended | 2025-02-04 | 2027-10-10 |
| AflacBT2303 · NCT06624371 Atovaquone Combined With Radiation in Children With Malignant Brain Tumors Single-country: United States (2 sites) Decision brief → | Ph1 | Emory University | recruiting | 2024-10-03 | 2027-10 |
| NCT06357377 A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Neonc Technologies, Inc. | recruiting | 2024-04-10 | 2027-06 |
| NCT05835687 Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | active not recruiting | 2023-04-28 | 2026-06-04 |
| NCT05768880 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2023-03-15 | 2028-01-15 |
| NCT05762419 FUS Etoposide for DMG Single-country: United States (1 site) Decision brief → | Ph1 | Columbia University | recruiting | 2023-03-09 | 2026-12 |
| CARMIGO · NCT05544526 CAR T Cells to Target GD2 for DMG Single-country: United Kingdom (1 site) Decision brief → | Ph1 | University College, London | recruiting | 2022-09-16 | 2027-08 |
| PNOC018 · NCT05478837 Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma Single-country: United States (1 site) Decision brief → | Ph1 | University of California, San Francisco | terminated | 2022-07-28 | 2026-01-31 |
| NCT05413304 Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis Single-country: United States (1 site) Decision brief → | Ph1 | National Cancer Institute (NCI) | active not recruiting | 2022-06-10 | 2025-10-21 |
| NCT05298995 GD2-CAR T Cells for Pediatric Brain Tumours Single-country: Italy (1 site) Decision brief → | Ph1 | Bambino Gesù Hospital and Research Institute | recruiting | 2022-03-28 | 2027-11 |
| NCT04978727 A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma 2 countries, 93% of sites in the US Decision brief → | Ph1 | Children's Oncology Group | active not recruiting | 2021-07-27 | 2027-12-31 |
| NCT04943848 rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG Single-country: United States (3 sites) Decision brief → | Ph1 | Ann & Robert H Lurie Children's Hospital of Chicago | recruiting | 2021-06-29 | 2026-09 |
| PEACH · NCT04837547 PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy Single-country: United States (3 sites) Decision brief → | Ph1 | University of Florida | recruiting | 2021-04-08 | 2027-09 |
| INTERCEPT-H3 · NCT04808245 A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas Single-country: Germany (8 sites) Decision brief → | Ph1 | German Cancer Research Center | active not recruiting | 2021-03-22 | 2026-11 |
| PNOC023 · NCT04732065 ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors 3 countries, 71% of sites in the US Decision brief → | Ph1 | Sabine Mueller, MD, PhD | recruiting | 2021-02-01 | 2027-05-31 |
| NCT04541082 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Single-country: United States (1 site) Decision brief → | Ph1 | Jazz Pharmaceuticals | active not recruiting | 2020-09-09 | 2027-03-31 |
| NCT04239092 9-ING-41 in Pediatric Patients With Refractory Malignancies. Single-country: United States (9 sites) Decision brief → | Ph1 | Actuate Therapeutics Inc. | terminated | 2020-01-23 | 2025-07-07 |
| NCT04196413 GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) Single-country: United States (1 site) Decision brief → | Ph1 | Stanford University | recruiting | 2019-12-12 | 2028-07-31 |
| NCT04185038 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | recruiting | 2019-12-04 | 2027-05 |
| NCT04099797 C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2019-09-23 | 2027-02 |
| NCT03914768 Immune Modulatory DC Vaccine Against Brain Tumor Single-country: China (1 site) Decision brief → | Ph1 | Shenzhen Geno-Immune Medical Institute | not yet recruiting | 2019-04-16 | 2029-05-31 |
| NCT03605550 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Single-country: United States (10 sites) Decision brief → | Ph1 | Nationwide Children's Hospital | active not recruiting | 2018-07-30 | 2024-03-01 |
| NCT03598244 Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors 2 countries, 92% of sites in the US Decision brief → | Ph1 | National Cancer Institute (NCI) | active not recruiting | 2018-07-26 | 2026-04-22 |
| CLOVER-2 · NCT03478462 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas 3 countries, 75% of sites in the US Decision brief → | Ph1 | Cellectar Biosciences, Inc. | active not recruiting | 2018-03-27 | 2027-06-30 |
| BRAVO · NCT03396575 Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) Single-country: United States (1 site) Decision brief → | Ph1 | University of Florida | terminated | 2018-01-11 | 2025-03-20 |
| NCT03389802 Phase I Study of APX005M in Pediatric Central Nervous System Tumors Single-country: United States (11 sites) Decision brief → | Ph1 | Pediatric Brain Tumor Consortium | completed | 2018-01-04 | 2023-09-30 |
| NCT02359565 Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma 2 countries, 92% of sites in the US Decision brief → | Ph1 | National Cancer Institute (NCI) | active not recruiting | 2015-02-10 | 2026-01-05 |
| CILENT · NCT01165333 Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Single-country: France (9 sites) Decision brief → | Ph1 | Centre Oscar Lambret | completed | 2010-07-19 | 2014-01 |